Evaxion A/S
EVAX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001828253
No open-market purchases or sales by Evaxion A/S insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $4.93M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Evaxion A/S changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 7 | 7 | 0 |
| Shares | 439.6K | 340.3K | −99.3K (−22.6%) |
| Value | $3.33M | $3.28M | −$51.0K (−1.5%) |
New holders (2)
Institutions that held Evaxion A/S at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Credit Suisse AG | 40,315 | $389.0K | 0.00% |
| Morgan Stanley | 200 | $2.00K | 0.00% |
Sold out (2)
Institutions that held Evaxion A/S at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Granite Point Capital Management, L.P. | 117,690 | $911.0K |
| Salem Investment Counselors Inc | 5 | $0 |